Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.
Teva Pharmaceuticals (TEVA) Q3 2025 earnings beat expectations with 33% growth in branded drugs led by Austedo. Stock surges 12% as innovative portfolio drives transformation.